drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically engineered to express chimeric antigen receptors for MHC-independent recognition of lymphoma antigens (e.g., CD19/CD20/CD22), leading to potent T-cell activation and cytolytic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors that recognize lymphoma antigens (e.g., CD19/CD20/CD22) in an MHC-independent manner; CAR engagement triggers CD3ΞΆ/co-stimulatory signaling, activating and expanding T cells to release cytotoxic mediators and kill antigen-positive tumor cells.
drug_name
CAR T-cell therapy
nct_id_drug_ref
NCT06202885